Were Daniel O'Day’s Gilead (GILD) share sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on February 25, 2026. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than decided opportunistically.

Gilead (GILD) CEO Daniel O'Day sells 15,000 shares in pre-set 10b5-1 trades

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Gilead Sciences Chairman & CEO Daniel O'Day reported open-market sales of 15,000 shares of Common Stock. The trades took place on June 1, 2026 in three transactions at prices around $131 per share. Footnotes state these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the timing was scheduled in advance rather than discretionary.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($1,971,847)

Net Sell 3 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 15,000 shs ($1.97M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,900	$131.0994	$1.43M
Sale	Common Stock	3,062	$132.2151	$405K
Sale	Common Stock	1,038	$132.9678	$138K

Holdings After Transaction: Common Stock — 621,667 shares (Direct, null)

Footnotes (1)

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold: 15,000 shares First sale size: 1,038 shares Second sale size: 3,062 shares +4 more

7 metrics

Shares sold 15,000 shares Total Common Stock sold on June 1, 2026

First sale size 1,038 shares Non-derivative Common Stock, code S

Second sale size 3,062 shares Non-derivative Common Stock, code S

Third sale size 10,900 shares Non-derivative Common Stock, code S

Reported sale price (example) $132.9678 per share One of the open-market sale prices

Price range (low) $130.66 per share Lowest sale price range from footnotes

Price range (high) $133.295 per share Highest sale price range from footnotes

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock, transaction_type: non-derivative"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: non-derivative for all Common Stock transactions"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 06:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		10,900	D	$131.0994⁽²⁾	621,667	D
Common Stock	06/01/2026		S⁽¹⁾		3,062	D	$132.2151⁽³⁾	618,605	D
Common Stock	06/01/2026		S⁽¹⁾		1,038	D	$132.9678⁽⁴⁾	617,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

4. Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Gilead Sciences (GILD) report for Daniel O'Day?

Gilead Sciences reported that Chairman & CEO Daniel O'Day sold 15,000 shares of Common Stock. The Form 4 shows three open-market sale transactions executed on June 1, 2026, reflecting a net reduction of 15,000 shares in his directly held position.

At what prices did Daniel O'Day sell Gilead (GILD) shares in this Form 4?

Daniel O'Day’s reported Gilead share sales occurred at prices around $131 per share. Footnotes specify sale-price ranges from $130.66 to $133.295, with detailed per-trade pricing available to the SEC, the issuer, or shareholders upon request.

How many Gilead (GILD) shares did Daniel O'Day sell in total?

The Form 4 reports that Daniel O'Day sold a total of 15,000 Gilead Sciences Common Stock shares. This total comes from three separate open-market sale transactions reported for June 1, 2026, all classified as non-derivative common stock sales.

What type of security did Daniel O'Day trade in this Gilead (GILD) Form 4?

All reported transactions involve Gilead Sciences Common Stock, classified as non-derivative securities. The Form 4 does not show any derivative exercises or conversions in this filing, and the derivative summary section is listed as empty.

Does the Gilead (GILD) Form 4 show any option exercises by Daniel O'Day?

No. The transaction codes disclosed are all “S” for sales of non-derivative Common Stock, with no M, C, or X codes. The derivative summary indicates zero derivative transactions and zero exercise shares in this particular filing.